Targeting the Paracaspase MALT1: A Potential Therapy to Overcome Ibrutinib Resistance in Relapsed/Refractory Mantle Cell Lymphoma Patients

被引：0
|
作者：
Jiang, Changying
Huang, Shengjian
Liu, Yang
Li, Carrie
Guo, Hui
Wang, Jeffrey
Lopez, Elyse
Zhang, Hui
Lorence, Elizabeth A.
Merolle, Maria
Balaji, Swathi
Ahmed, Makhdum
Nomie, Krystle
Lin, Xin
Zhang, Liang
Wang, Michael
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
574
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Targeting the paracaspase MALT1: A potential therapy to overcome ibrutinib resistance in relapsed/refractory MCL patients
    Jiang, Changying
    Huang, Shengjian
    Lin, Xin
    Wang, Michael
    Zhang, Liang
    CANCER RESEARCH, 2017, 77
  • [2] Oncogenic MALT1 Promotes Cell Survival and Mediates Ibrutinib Resistance and Ibrutinib-Venetoclax Resistance in Mantle Cell Lymphoma
    Jiang, Vivian Changying
    Lian, Junwei
    Huang, Shengjian
    Zhang, Shaojun
    Liu, Yang
    Wang, Linghua
    Wang, Michael
    BLOOD, 2020, 136
  • [3] Molecular Pathways: Targeting MALT1 Paracaspase Activity in Lymphoma
    Fontan, Lorena
    Melnick, Ari
    CLINICAL CANCER RESEARCH, 2013, 19 (24) : 6662 - 6668
  • [4] Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
    Wang, Michael L.
    Rule, Simon
    Martin, Peter
    Goy, Andre
    Auer, Rebecca
    Kahl, Brad S.
    Jurczak, Wojciech
    Advani, Ranjana H.
    Romaguera, Jorge E.
    Williams, Michael E.
    Barrientos, Jacqueline C.
    Chmielowska, Ewa
    Radford, John
    Stilgenbauer, Stephan
    Dreyling, Martin
    Jedrzejczak, Wieslaw Wiktor
    Johnson, Peter
    Spurgeon, Stephen E.
    Li, Lei
    Zhang, Liang
    Newberry, Kate
    Ou, Zhishuo
    Cheng, Nancy
    Fang, Bingliang
    McGreivy, Jesse
    Clow, Fong
    Buggy, Joseph J.
    Chang, Betty Y.
    Beaupre, Darrin M.
    Kunkel, Lori A.
    Blum, Kristie A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (06): : 507 - 516
  • [5] Masking MALT1: the paracaspase's potential for cancer therapy
    Vucic, Domagoj
    Dixit, Vishva M.
    JOURNAL OF EXPERIMENTAL MEDICINE, 2009, 206 (11): : 2309 - 2312
  • [6] Targeting B-cell lymphomas with inhibitors of the MALT1 paracaspase
    Haifinger, Stephan
    Lenz, Georg
    Thome, Margot
    CURRENT OPINION IN CHEMICAL BIOLOGY, 2014, 23 : 47 - 55
  • [7] Efficacy and safety of ibrutinib in Japanese patients with relapsed or refractory mantle cell lymphoma
    Maruyama, Dai
    Nagai, Hirokazu
    Fukuhara, Noriko
    Kitano, Toshiyuki
    Ishikawa, Takayuki
    Shibayama, Hirohiko
    Choi, Ilseung
    Hatake, Kiyohiko
    Uchida, Toshiki
    Nishikori, Momoko
    Kinoshita, Tomohiro
    Matsuno, Yoshihiro
    Nishikawa, Tomoaki
    Takahara, Satoko
    Tobinai, Kensei
    CANCER SCIENCE, 2016, 107 (12) : 1785 - 1790
  • [8] Ibrutinib in refractory mantle cell lymphoma or relapsed data update
    Paillassa, Jerome
    HEMATOLOGIE, 2015, 21 (05): : 257 - 259
  • [9] A retrospective analysis of ibrutinib outcomes in relapsed or refractory mantle cell lymphoma
    Lee, Yong-Pyo
    Jung, Ye Ji
    Cho, Junhun
    Ko, Young Hyeh
    Kim, Won Seog
    Kim, Seok Jin
    Yoon, Sang Eun
    BLOOD RESEARCH, 2023, 58 (04) : 208 - 220
  • [10] Ibrutinib and Ixazomib in Relapsed/Refractory Mantle Cell Lymphoma: Precog 0404
    Cohen, Jonathon B.
    Jegede, Opeyemi
    Portell, Craig A.
    Hamadani, Mehdi
    Diefenbach, Catherine S.
    David, Kevin A.
    Fletcher, Christopher D.
    Landsburg, Daniel J.
    Mantha, Suparna
    Kahl, Brad S.
    BLOOD, 2022, 140 : 6487 - 6488
12345